Oculis Holding AG (NASDAQ:OCS) Short Interest Down 54.1% in July

Key Points

• Oculis Holding AG's short interest dropped by 54.1% in July, decreasing from 20,900 shares to 9,600 shares, indicating a low level of short-selling at approximately 0.0% of the company's total stock.
• The company's stock has a market cap of $781.51 million, with a PE ratio of -6.78 and trading within a twelve-month range between $10.79 and $23.08.
• Chardan Capital has raised its price target for Oculis from $28.00 to $33.00, maintaining a "buy" rating, which reflects positive analyst outlook on the company's growth potential.

Oculis Holding AG (NASDAQ:OCS - Get Free Report) was the recipient of a significant decline in short interest in the month of July. As of July 31st, there was short interest totaling 9,600 shares, adeclineof54.1% from the July 15th total of 20,900 shares. Currently,0.0% of the company's shares are short sold. Based on an average daily volume of 21,100 shares, the short-interest ratio is currently 0.5 days. Based on an average daily volume of 21,100 shares, the short-interest ratio is currently 0.5 days. Currently,0.0% of the company's shares are short sold.

Oculis Trading Up 1.2%

Shares of OCS stock traded up $0.2050 during trading hours on Friday, reaching $18.0050. 8,411 shares of the company's stock were exchanged, compared to its average volume of 44,427. The stock's 50 day moving average is $18.41 and its 200-day moving average is $18.74. The company has a market cap of $786.10 million, a price-to-earnings ratio of -6.82 and a beta of 0.27. Oculis has a fifty-two week low of $11.56 and a fifty-two week high of $23.08.

Oculis (NASDAQ:OCS - Get Free Report) last issued its quarterly earnings results on Thursday, August 21st. The company reported ($0.59) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.53) by ($0.06). Oculis had a negative return on equity of 92.95% and a negative net margin of 13,788.70%.The business had revenue of $0.25 million for the quarter, compared to analyst estimates of $0.14 million. Equities analysts anticipate that Oculis will post -2.09 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on the company. HC Wainwright upped their target price on Oculis from $32.00 to $33.00 and gave the stock a "buy" rating in a report on Friday. Chardan Capital upped their target price on Oculis from $28.00 to $33.00 and gave the stock a "buy" rating in a report on Friday, May 9th. Three investment analysts have rated the stock with a Buy rating, According to data from MarketBeat, the stock has an average rating of "Buy" and an average target price of $35.67.

Institutional Investors Weigh In On Oculis

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Pivotal bioVenture Partners Investment Advisor LLC boosted its stake in shares of Oculis by 32.4% during the 1st quarter. Pivotal bioVenture Partners Investment Advisor LLC now owns 2,300,774 shares of the company's stock worth $43,784,000 after acquiring an additional 563,078 shares in the last quarter. Aberdeen Group plc boosted its stake in shares of Oculis by 24.1% during the 1st quarter. Aberdeen Group plc now owns 1,253,119 shares of the company's stock worth $23,847,000 after acquiring an additional 243,695 shares in the last quarter. SR One Capital Management LP purchased a new stake in shares of Oculis during the 1st quarter worth about $6,137,000. Alyeska Investment Group L.P. purchased a new stake in shares of Oculis during the 1st quarter worth about $2,499,000. Finally, Compagnie Lombard Odier SCmA boosted its stake in shares of Oculis by 11.5% during the 2nd quarter. Compagnie Lombard Odier SCmA now owns 97,000 shares of the company's stock worth $1,883,000 after acquiring an additional 10,000 shares in the last quarter. 22.30% of the stock is owned by institutional investors and hedge funds.

Oculis Company Profile

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.